1449412-80-9

Basic information

• Product Name: 4-broMo-N-cyclopropyl-3-nitrobenzenesulfonaMide
• Synonyms: 4-broMo-N-cyclopropyl-3-nitrobenzenesulfonaMide
• CAS NO: 1449412-80-9
• Molecular Formula: C₉H₉BrN₂O₄S
• Molecular Weight: 321.14776
• Mol File: 1449412-80-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-broMo-N-cyclopropyl-3-nitrobenzenesulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-N-cyclopropyl-3-nitrobenzenesulfonaMide(1449412-80-9)
• EPA Substance Registry System: 4-broMo-N-cyclopropyl-3-nitrobenzenesulfonaMide(1449412-80-9)

Safety Data

• Hazardous Substances Data: 1449412-80-9(Hazardous Substances Data)

Upstream product

• 4750-22-5 4-bromo-3-nitrobenzene-1-sulfonyl chloride 
• 765-30-0 Cyclopropylamine 
• 577-19-5 2-nitrophenyl bromide 

Downstream Products

• 1604060-07-2 3-amono-N-cyclopropyl-4-(thiophen-3-yl)benzenesulfonamide 
• 1604059-88-2 N-cyclopropyl-3-nitro-4-(thiophen-3-yl)benzenesulfonamide 

Relevant articles and documents

Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors

A series of novel 2-arylbenzimidazoles have been designed, synthesized and evaluated for their inhibitory activity against IDH2 R140Q mutant. The preliminary results indicated that four compounds 7b, 7c, 7m and 7r displayed the potent inhibitory activity against IDH2 R140Q mutant. Among them, compound 7c showed the highest inhibitory activity, with the IC50 value of 0.26 μM, which was more active than positive control enasidenib. The exquisite selectivity of 7c for IDH2 R140Q mutant isoform was demonstrated by the poor activity against the IDH1 R132C mutant, IDH1 R132H mutant, wild-type IDH1, IDH2 R172K mutant and the wild-type IDH2.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).